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Abstract 
Atherosclerotic cardiovascular diseases are the leading cause of adverse outcomes in patients with type 2 diabetes, 
and all new anti‑diabetic agents are mandated to undergo cardiovascular outcome trials (CVOTs). Glucagon‑like 
peptide‑1 receptor agonists (GLP‑1 RA) are incretin mimetics that reduce blood glucose levels with a low associated 
risk of hypoglycaemia. CVOTs with different GLP‑1 RAs yielded different results in terms of major cardiovascular com‑
posite outcome (MACE), with some trials showing superiority in the treatment arm, whereas other simply displayed 
non‑inferiority. More importantly, the significance of each component of MACE varied between drugs. This begs the 
question of whether these differences are due to dissimilarities between drugs or other factors, namely trial design, 
are at the root of these differences. We analyse the trial designs for all CVOTs with GLP‑1 RAs and highlight important 
differences between them, namely in terms of definition of established cardiovascular disease, and discuss how these 
differences might explain the disparate results of the trials and preclude direct comparisons between them. We con‑
clude that a fair comparison between GLP‑1 RA CVOTs would involve post‑hoc analysis re‑grouping the patients into 
different cardiovascular risk categories based upon their baseline clinical parameters, in order to even out the criteria 
used to classify patients.
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Background
Diabetes is one of the most prevalent chronic diseases 
worldwide. According to the 2019 International Diabetes 
Federation report, global diabetes prevalence, between 
20 and 79 years of age, is estimated to be 9.3% (463 mil-
lion people) and is projected to increase by 25% in 2030 
and 51% in 2045 [1].
Diabetes is a devastating disease, associated with an 
ominous prognosis. Diabetes relative mortality rates 
were reported to be approximately twice to 4 times as 
high compared with individuals without diabetes, with an 
estimated 4.2 million deaths directly caused by the dis-
ease or by its complications in 2019, almost half of them 
before the age of 60  years [1]. Diabetes is also a major 
cause of morbidity. Amongst diabetes-related complica-
tions, atherosclerotic cardiovascular diseases (ASCVD) 
remain the leading cause of mortality and adverse out-
comes in patients with type 2 diabetes mellitus (T2D) [2]. 
Events of ASCVD in diabetes mellitus include coronary 
heart disease, ischemic stroke, peripheral artery disease 
(PAD), and heart failure (HF) [2]. These manifestations 
generally occur earlier and are more severe and diffuse 
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Emerging Risk Factors Collaboration data, their combi-
nation has a multiplicative effect on mortality risk [3].
Even though in recent years the incidence of diabe-
tes-related cardiovascular (CV) complications in T2D 
patients have been decreasing, these remain higher than 
in non-diabetics [4–6]. The control of five risk factors 
for cardiovascular disease in T2D patients–elevated gly-
cated haemoglobin (HbA1c) level, elevated low-density 
lipoprotein cholesterol level, albuminuria, smoking, and 
elevated blood pressure – to within normal range brings 
almost equals the risks of death, stroke, and myocardial 
infarction of the general population. In a cohort study 
including 271,174 patients with T2D and matched with 
1,355,870 controls, the risk of hospitalization for HF was 
consistently higher among patients with diabetes than 
among controls. A HbA1c level outside the target range 
was the strongest predictor of stroke and acute myocar-
dial infarction [5]. We can assume that evidence-based 
secondary prevention therapies, although effective, are 
not able to close this gap between diabetics and non-dia-
betics, despite optimal glycemic control [7–9]. Likewise, 
coronary revascularization has worse outcomes in the 
presence of diabetes, with higher rates of stent thrombo-
sis in percutaneous revascularization and worse survival 
after coronary artery bypass grafting (CABG), particu-
larly in insulin treated patients [10, 11]. In multivessel 
disease, CABG has better results than percutaneous cor-
onary intervention (PCI) with drug-eluting stents in pre-
venting the occurrence of non-fatal myocardial infarction 
(MI), non-fatal stroke or all-cause death [12] and lower 
rates of all-cause death at a median follow-up of 7.5 years 
[13].
The risk of CV events is associated with hyperglyce-
mia, and is increased even with glycemic levels below 
the threshold for diabetes, although this association is 
stronger for microvascular complications [14]. Para-
doxically, therapeutic strategies used for intensive glyce-
mic control have failed to prove beneficial in preventing 
major adverse CV events (MACE) in comparison to 
less stringent strategies, as shown by the results of the 
ACCORD (Action to Control Cardiovascular Risk in 
Diabetes) [15] and the ADVANCE (Action in Diabetes 
and Vascular Disease: Preterax and Diamicron Modified 
Release Controlled Evaluation) [16] and VADT (Vet-
erans Affairs Diabetes Trial) [17] trials in 2008. In the 
ACCORD trial a significant increase of mortality that led 
to interruption of the study was observed, but that seem 
to be due to significant glycemic variability as those who 
experienced mortality didn’t have a significant reduc-
tion in HbA1c despite forced titration of their therapy. 
Insulin and sulfonylureas were also used in that study. 
These studies used the glucose-lowering drugs available 
at the time, including drugs from pharmacological classes 
classically associated with a significant risk for hypogly-
cemia. In the light of new CV outcomes trials (CVOTs) 
results, we should revise our appraisal of the ACCORD 
and ADVANCE trials. Perhaps the focus should not 
be only on achieving the lowest glycemic levels, but 
rather on the mechanisms by which glycemic lowering 
is attained and collateral metabolic benefits obtained. 
Moreover, the non-glycemic effects of these new drug 
classes, impacting blood pressure and renal damage, may 
add to their beneficial effect on cardiovascular events.
Although the majority of diabetes-associated deaths 
in the ACCORD and ADVANCE trials were CV and 
the association of glycemic levels with MACE was only 
modest, it is interesting to see how the focus of previous 
trials with diabetic drugs was glucose lowering and not 
CV outcomes. Despite the positive outcomes of met-
formin use in the United Kingdom Prospective Diabetes 
Study (UKPDS) [18], it was a meta-analysis of trials with 
rosiglitazone, showing an increase in the rate of MI and a 
numerical increase in all-cause death [19], that alarmed 
regulatory agencies and, since 2008, prompted safety tri-
als evaluating CV outcomes for new glucose-lowering 
agents.
Glucagon-like peptide-1 receptor agonists (GLP-1 RA) 
are glucose-lowering drugs used in the treatment of T2D, 
which carry low risk for hypoglycemia and induce weight 
loss [20]. CVOTs with GLP-1 RA included a variable 
number of patients with established CV diseases (eCVD) 
or at high risk for CV events, with different inclusion cri-
teria (Tables  1 and 2). These differences make compari-
sons between trials impossible and may have influenced 
trial results. For this reason, we found it pertinent to 
review the different CVOTs performed with GLP-1 RA 
and perform a comparative analysis between them, high-
lighting the different study designs for each one.
Main characteristics of the GLP‑1 RA CVOTs
ELIXA
The Evaluation of Lixisenatide in Acute Coronary Syn-
drome (ELIXA) trial [21, 22] was a multicentre, rand-
omized, double-blind, placebo-controlled trial to assess 
the effects of daily subcutaneous lixisenatide on CV out-
comes in patients with T2D who had had a recent acute 
coronary event.
Patients with T2D were identified for a spontaneous 
acute coronary syndrome (ACS) within 180 days follow-
ing hospitalization. ACS was defined as either segment 
elevation myocardial infarction (STEMI), non-STEMI, 
or unstable angina (UA). Inclusion criteria also required 
elevation of at least one cardiac biomarker (troponin or 
creatine kinase-MB isoenzyme).
The primary endpoint in the time-to-event analysis was 
a composite for a first episode of any of the following: 
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death from CV causes, nonfatal MI, nonfatal stroke, or 
hospitalization for UA. This was the only of the analyzed 
trials to include UA as part of the primary endpoint, thus 
having a 4-point MACE primary outcome.
The ELIXA trial included 6068 patients, all of which 
had eCVD at baseline if one considers the ACS crite-
ria, and who were followed for a relatively short time 
(2.1 years average follow-up period).
LEADER
The Liraglutide Effect and Action in Diabetes: Evaluation 
of Cardiovascular Outcome Results (LEADER) trial [23, 
24] was a multicenter, double-blind, placebo-controlled 
trial designed to assess the long-term effects of subcuta-
neous once-daily liraglutide on CV outcomes and other 
clinically important events in patients with T2D who 
were at high risk for CV disease (CVD). It was a post-
approval trial designed to test primarily for non-inferior-
ity, and thus the non-inferiority margin of the upper limit 
of the 95% Confidence Interval (CI) for MACE (primary 
outcome) was set at 1.3.
Two groups of patients were considered for enrol-
ment: a) patients aged ≥ 50  years with eCVD [defined 
as: prior MI; prior stroke or transient ischemic attack; 
prior coronary, carotid or peripheral arterial revascu-
larization; > 50% stenosis of coronary, carotid, or lower 
extremity arteries; history of symptomatic coronary heart 
disease documented by positive exercise stress test or any 
cardiac imaging or unstable angina with electrocardio-
graphic (ECG) changes; asymptomatic cardiac ischemia 
documented by positive nuclear imaging test, exercise 
test or dobutamine stress echo; chronic HF [New York 
Heart Association (NYHA) class II or III)] or chronic 
renal failure [defined as an estimated glomerular filtra-
tion rate (eGFR) of less than 60 mL per minute per 1.73 
 m2], and b) patients aged ≥ 60 years with at least one high 
CVD risk factor (presence of microalbuminuria or pro-
teinuria; hypertension and left ventricular hypertrophy 
by ECG or imaging; left ventricular systolic or diastolic 
dysfunction by imaging; ankle-brachial index < 0.9).
A total of 9340 patients were enrolled, 81.3% of which 
had eCVD at baseline, and were followed for an average 
of 3.8 years.
SUSTAIN‑6
The Trial to Evaluate Cardiovascular and Other Long-
term Outcomes with Semaglutide in Subjects with Type 
2 Diabetes (SUSTAIN-6) [25] was a pre-approval study 
designed to evaluate the non-inferiority of once-weekly 
subcutaneous semaglutide, as compared with placebo, 
in terms of CV safety. Being a pre-approval trial, the 
non-inferiority margin of the upper limit of the 95% 
CI for MACE was set at 1.8; for this reason, the sam-
ple size (N = 3297) is smaller than the samples of major 
post-approval CVOTs with antidiabetic drugs (as can be 
appreciated from Tables 1 and 3).
Key inclusion criteria were age ≥ 50 years with presence 
of eCVD or presence of chronic kidney disease stage 3 or 
higher (eGFR less than 60 mL per minute per 1.73  m2), or 
age ≥ 60 years and the presence of an additional CV risk 
factor. Established CVD included previous CV, cerebro-
vascular disease or PAD, and was defined according to 
the following criteria: prior MI, prior stroke or prior tran-
sient ischemic attack, prior coronary, carotid or periph-
eral arterial revascularization, more than 50% stenosis 
on angiography or imaging of coronary, carotid or lower 
Table 1 Trial design
CI confidence interval, CV cardiovascular, MACE major adverse cardiovascular outcome, MI myocardial infarction, UA unstable angina
ELIXA [21] LEADER [23] SUSTAIN‑6 [25] EXSCEL [26] Harmony 
Outcomes [29]
PIONEER 6 [31] REWIND [33]
NCT number NCT01147250 NCT01179048 NCT01720446 NCT01144338 NCT02465515 NCT02692716 NCT01394952















Trial phase III (pre‑approval) IIIb (post‑
approval)




III (pre‑approval) III/IV (post‑
approval)






(upper range of 
the two‑sided 
95% CI < 1.3)
Non‑inferiority 
(upper limit 
of the 95% 
CI  < 1.8)
Superiority 
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Primary outcome 4‑point MACE: 
CV death, 




CV death, MI, or 
stroke
3‑point MACE: 
CV death, MI, or 
stroke
3‑point MACE: 
CV death, MI, or 
stroke
3‑point MACE: 
CV death, MI, 
or stroke
3‑point MACE:
CV death, MI, or 
stroke
3‑point MACE:
CV death, MI, or 
stroke
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Table 2 Trial key inclusion criteria
ELIXA [21]  LEADER [23] SUSTAIN-6 
[25]








   > 30 with spontaneous ACS within 180 
days of enrollment 
≥ DVCehtiw04
≥ 50 with eCVD or CKD stage III or higher 
or ≥ 60 with 1 or more CV risk factor 
≥ 50 with eCVD or ≥ 55 with CKD or other 




≥ 5.5% and ≤ 11.0% 




   None 
   Microalbuminuria or Albuminuria  
   Hypertension and LV Hypertrophy  
   LV systolic or diastolic dysfuncon  
9.0<xednIlaihcarB-elknA
   Tobacco useA 
   Use of lipid modifying therapy or LDL ≥ 3.4 
mmol/LA
   HDL cholesterol < 1.0 mmol/L for men or < 
1.3 mmol/L (women) or triglycerides ≥ 2.3 
mmol/LA
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Table 2 (continued)
   Use of ≥ 1 BP drug or untreated systolic BP 
≥ 140 mm Hg or diastolic BP ≥ 95 mm Hg) A






   Prior strokeB
   Prior coronary, carod or peripheral 
arterial revascularizaon 
B
   >50% stenosis of coronary, carod, or 
lower extremity arteries 
C
   History of symptomac coronary heart 
disease 
   Asymptomac cardiac ischemia  
   Chronic HF (NYHA class II or III)  
eruliaflanercinorhC C* 
   ACS defined as either: STEMI; non-STEMI; 
UA 
   Unstable angina with ECG changes   
   CAD with either: history of spontaneous 
MI at least 30 days before screening; CAD 
with ≥50% stenosis in one or more major 
epicardial coronary arteries determined by 
invasive angiography; or history of surgical 
or percutaneous (balloon and/or stent) 
coronary revascularizaon procedure (at 
least 30 days before screening for 
percutaneous procedures and at least 5 
years before screening for CABG) 
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Table 2 (continued)
   Cerebrovascular  disease with either: 
history of ischemic stroke at least 90 days 
before study entry; carod arterial disease 
with ≥50% stenosis documented by carod 
ultrasound, magnec resonance imaging or 
angiography, with or without symptoms of 
neurologic deficit; or carod vascular 
procedure at least 30 days before screening 
   PAD with either: intermient claudicaon 
and ankle/brachial index <0.9 in at least 1 
ankle; prior nontraumac amputaon; or 
peripheral vascular procedure due to 
peripheral arterial ischemia 
   Prior unstable angina hospitalizaonB
   Imaging evidence of myocardial 
ischaemiaB
   Percutaneous coronary intervenonB
   Myocardial ischaemiaC
   LV hypertrophyC
   AlbuminuriaC
Concomitant diabetes medicaon allowed
   Any 
AR1-PLGtpecxeynA
   Up to 3 oral glucose-lowering agents (incl. 
DPP-4 inhibitors) 
   Any except GLP-1 RA, DPP-4 inhibitors or 
insulin other than basal or premixed 
   Any except GLP-1 RA, DPP-4 inhibitors or 
pramlinde 
   Insulin and up to 2 oral glucose-lowering 
agents and  
Run-in adherence
   None 
≥ %05
%001
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extremities arteries, history of symptomatic coronary 
heart disease (documented by positive exercise stress 
test or any cardiac imaging) or unstable angina with ECG 
changes, asymptomatic cardiac ischemia (documented 
by positive nuclear imaging test or exercise test or stress 
echo or any cardiac imaging) or chronic HF NYHA class 
II-III. In the group of patients without eCVD, selection 
criteria based on the presence of risk factors included: 
persistent microalbuminuria (30‒299 mg/g) or proteinu-
ria, hypertension and left ventricular hypertrophy (by 
ECG or imaging), left ventricular systolic or diastolic dys-
function by imaging, ankle/brachial index less than 0.9.
Overall, 83.0% of patients had eCVD, but all were at 
high CV risk, and patients were followed for a relatively 
short time (2.1  years) (Table  3), raising questions on 
whether these results would be generalizable for a more 
diverse population or for longer period of treatment [25].
EXSCEL
EXSCEL (EXenatide Study of Cardiovascular Event 
Lowering trial) [26–28] was a multinational, placebo-
controlled, double-blind, parallel-group pragmatic trial 
which randomized patients with T2D to receive once-
weekly subcutaneous exenatide or matching placebo 
(unloaded microspheres), in addition to their usual care. 
It assessed the impact of once-weekly exenatide therapy 
in 14,752 patients, with or without known CVD.
The EXSCEL trial population was adults with T2D, 
with or without additional CV risk factors or prior CV 
events, and randomization targeted approximately 70% 
with a history of a cardiovascular event and 30% without 
known CVD, followed for 3.2 years on average.
A prior CV event was defined as at least one of the 
following: a) history of a major clinical manifestation of 
coronary artery disease, i.e., MI, surgical or percutaneous 
(balloon and/or stent) coronary revascularization proce-
dure, or coronary angiography showing at least one ste-
nosis ≥ 50% in a major epicardial artery or branch vessel, 
b) ischemic cerebrovascular disease, including: history 
of ischemic stroke (strokes not known to be hemor-
rhagic will be allowed as part of this criterion; transient 
ischemic attacks are not included), history of carotid 
arterial disease with ≥ 50% stenosis documented by 
carotid ultrasound, magnetic resonance imaging, or angi-
ography, with or without symptoms of neurologic deficit, 
or c) atherosclerotic peripheral arterial disease, as docu-
mented by objective evidence such as amputation due to 
vascular disease, current symptoms of intermittent clau-
dication confirmed by an ankle-brachial pressure index 
or toe-brachial pressure index less than 0.9, or history of 
surgical or percutaneous revascularization procedure.
Being a pragmatic trial, EXSCEL aimed to assess the 
effectiveness of exenatide in a setting similar to the real 
world, with broad inclusion criteria and streamlined pro-
cedures. It allowed a broad range of concomitant anti-
diabetic drugs, including DPP-4 inhibitors, which act on 
the same incretin system as GLP-1 RA. There was also no 
ACS acute coronary syndrome, BP blood pressure, CAD coronary artery disease, CKD chronic kidney disease, CV cardiovascular, ECG electrocardiogram, eCVD  
established cardiovascular disease, HbA1c haemoglobin A1c (glycated haemoglobin), HDL high-density lipoprotein, HF heart failure, LDL low-density lipoprotein, LV 
left ventricle, MI myocardial infarction, NYHA New York Heart Association classification, PAD peripheral artery disease, STEMI segment elevation myocardial infarction, 
TIA transient ischemic attack, UA unstable angina, Grey shade inclusion criteria adopted in the trial 
A – age 50–54 only; B—≥ 50 years; C – 55–59 years; *estimated glomerular filtration rate < 60 mL per minute per 1.73  m2
Table 3 Baseline population characteristics and primary outcome results
CKD chronic kidney disease, eCVD established cardiovascular disease, eGFR estimated glomerular filtration rate, HbA1c haemoglobin A1c (glycated haemoglobin), HF 
heart failure, NYHA New York Heart Association classification
ELIXA [22] LEADER [24] SUSTAIN‑6 [25] EXSCEL [27, 28] Harmony 
Outcomes 
[30]
PIONEER 6 [32] REWIND [34]
N 6068 9340 3297 14,752 9463 3183 9901
Female 30.7% 35.7% 39.3% 38.0% 30.6% 31.6% 46.3%
Age (mean) 60.3 years 64.2 years 64.6 years 62.7 years 62.7 years 66.1 years 66.2 years
HbA1c (mean) 7.7% 8.7% 8.7% 8.0% 8.7% 8.2% 7.2%
Diabetes duration 9.3 years 12.8 years 13.9 years 12.0 years 13.8 years 14.9 years 9.5 years
eCVD
(according to each study’s defini‑
tion)
100% (ACS) 81.3% 83.0% 73.1% 100% 84.6% 31.5%
HF (NYHA I‑III) 17.8% 23.6% 16.2% 20.2% 8.6%
CKD (eGFR < 60 mL/min/1.73  m2) 23.2% 24.7% 28.5% 18.6% 22.6% 26.9% 22.2%
Follow‑up (median) 2.1 years 3.8 years 2.1 years 3.2 years 1.5 years 1.3 years 5.4 years
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run-in period to screen for adherence, again making it 
more akin to a real world setting.
Harmony outcomes
Harmony Outcomes (brief title: Effect of Albiglutide, 
When Added to Standard Blood Glucose Lowering Ther-
apies, on Major Cardiovascular Events in Subjects With 
Type 2 Diabetes Mellitus) [29, 30] was a randomized, 
double-blind, placebo controlled trial of the effect of albi-
glutide on MACE in patients with T2D and established 
CVD. The trial enrolled 9463 participants aged ≥ 40 years 
with T2D, prior ASCVD, and suboptimal glycemic con-
trol. Participants were assigned in a 1:1 ratio to albiglu-
tide 30 mg (potentially increasing to 50 mg) or matching 
placebo, administered once weekly by subcutaneous 
injection. The trial continued until 766 confirmed pri-
mary outcome events (cardiovascular death, MI, or 
stroke) occurred, over an average follow-up of 1.5 years.
The inclusion criteria were age ≥ 40 years with a diag-
nosis of T2D, eCVD, and HbA1c > 7.0% (53 mmol/mol). 
Established CVD was defined as at least one of the fol-
lowing: a) coronary artery disease with either: docu-
mented history of spontaneous MI, at least 30  days 
before screening; documented coronary artery disease 
with ≥ 50% stenosis in one or more major epicardial cor-
onary arteries, determined by invasive angiography; or 
history of surgical or percutaneous (balloon and/or stent) 
coronary revascularization procedure (at least 30  days 
before screening for percutaneous procedures and at 
least 5 years before screening for CABG), b) cerebrovas-
cular disease with either: documented history of ischemic 
stroke at least 90 days before study entry; carotid arterial 
disease with ≥ 50% stenosis documented by carotid ultra-
sound, magnetic resonance imaging or angiography, with 
or without symptoms of neurologic deficit; or carotid 
vascular procedure (e.g., stenting or surgical revascu-
larization), at least 30  days before screening, or c) PAD 
with either: intermittent claudication and ankle/brachial 
index < 0.9 in at least 1 ankle; or prior non-traumatic 
amputation, or peripheral vascular procedure (e.g., stent-
ing or surgical revascularization), due to peripheral arte-
rial ischemia.
Besides the ELIXA, in which all patients had a previous 
ACS (see above), the Harmony Outcomes was the only 
CVOT in which the entire population had eCVD.
PIONEER 6
The CV safety of the oral formulation of semaglutide was 
evaluated in the PIONEER 6 randomized controlled trial 
(official title: A Trial Investigating the Cardiovascular 
Safety of Oral Semaglutide in Subjects With Type 2 Dia-
betes) [31, 32]. This was also a pre-approval non-inferi-
ority trial that included 3183 patients and demonstrated 
the CV safety of the drug. Inclusion criteria and primary 
outcome were exactly the same used in the SUSTAIN-6 
trial [25] (Table 1 and 2), and 84.6% of the patients were 
selected due to the presence of CV or chronic renal dis-
ease (stage 3 or above—eGFR less than 60 mL per minute 
per 1.73  m2). Patients were followed for an even shorter 
time (1.3 years) than in the SUSTAIN-6 trial.
REWIND
The Researching cardiovascular Events with a Weekly 
INcretin in Diabetes (REWIND) trial [33, 34] was a 
post-approval study designed to evaluate if the addition 
of once-weekly subcutaneous dulaglutide to standard of 
care was able to safely reduce the incidence of MACE 
in people with T2D aged ≥ 50  years. As in SUSTAIN-6, 
patient selection was based in a mixture of characteristics 
including age, presence of CVD and presence of risk fac-
tors. However, the selection of patients was more complex 
and included three subgroups: patients aged ≥ 50  years 
with eCVD [i.e., a previous MI, ischemic stroke, revas-
cularization (coronary, carotid or peripheral), hospi-
tal admission for unstable angina, or imaging evidence 
of myocardial ischemia]; patients aged ≥ 55  years with 
subclinical CVD (defined by the presence of myocardial 
ischemia, coronary, carotid, or lower extremity artery 
stenosis exceeding 50% or left ventricular hypertrophy), 
eGFR less than 60 mL/min per 1.73  m2, or albuminuria; 
patients aged ≥ 60  years with two additional risk fac-
tors among tobacco use, dyslipidemia, hypertension, 
or abdominal obesity. However, when considering the 
groups with and without CV disease for reporting the 
results, patients were categorized as having CV disease 
if they had corresponded to the first group, with previ-
ous history of MI, ischemic stroke, unstable angina with 
ECG changes, myocardial ischemia on imaging or stress 
test, or coronary, carotid, or peripheral revascularization. 
Using the latter definition, 31.5% of the included popula-
tion was considered to have CVD, making it the GLP-1 
RA CVOT with the lowest percentage of eCVD popula-
tion (Table 3). Nonetheless, as noted above (and systema-
tized in Table 2), the criteria for eCVD in this trial differ 
somehow from the other CVOTs. The REWIND trial also 
included the highest percentage of females (46.3%), the 
population with the average lowest HbAc1 levels (7%), 
and the longest follow-up time (5.4 years) of all the trials 
analyzed (Table 3).
FREEDOM‑CVO
The FREEDOM-CVO safety trial was the fourth and 
final phase 3 clinical study of the FREEDOM program. 
It was a placebo-controlled cardiovascular outcomes 
study designed to meet the pre-approval safety assess-
ment requirements set out in the U.S. Food and Drug 
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Administration’s (FDA) Guidance for Industry to evalu-
ate cardiovascular risk for new therapies to treat T2D. 
FREEDOM-CVO evaluated the safety of ITCA 650 at 
60 µg per day vs. placebo in just over 4,000 patients on a 
variety of approved standard of care anti-diabetes thera-
pies. ITCA 650 is a miniature osmotic pump system that 
is designed to deliver continuous subcutaneous release 
of exenatide. The duration of the study was dependent 
on event-based outcomes, and lasted just under 3 years, 
reaching the target number of cardiovascular events in 
the fourth quarter of 2015. The average treatment dura-
tion in FREEDOM-CVO was 1.2 years (ClinicalTrials.gov 
Identifier: NCT01455896). Age eligibility for the study 
was 40  years and older; other inclusion criteria stipu-
lated that patients should have HbA1c > 6.5%, a history of 
coronary, cerebrovascular or peripheral artery disease, or 
multiple CV risk factors. There were a total of 160 strict 
MACE events observed in the FREEDOM-CVO trial. 
The overall safety and tolerability data for ITCA 650 was 
consistent with the three phase 3 trials that have already 
been presented and documented in the published litera-
ture for exenatide and other GLP-1 RA therapies [35–38]. 
ITCA submitted a new application to FDA for approval 
in October 2019. Non-inferiority was described but final 
results were not published so it in depth analysis will not 
be considered in this paper.
Summary and discussion of the GLP‑1 RA CVOTs 
results
All the GLP-1 RA CVOTs had an identical composite 
3-point MACE primary outcome, including CV death, 
non-fatal MI or stroke (Table 1). The only exception was 
the ELIXA trial, which included an additional compo-
nent of UA (4-point MACE) (Table 1). Nonetheless, there 
were different results obtained across the different trials, 
with some CVOTs showing superiority in the treatment 
arm, whilst others only demonstrated non-inferiority 
(Table  4). Even in trials which showed a positive effect, 
the significance of each component of the MACE out-
come varied (see Table  4). This raises the question of 
whether or not we can consider the cardioprotective 
effects of GLP-1 RA as a class effect. It could in fact be 
the case that differences between drugs of this pharmaco-
logical class could explain the conflicting results, namely 
the long/short-action of the different GLP-1 RA and their 
molecule structure [39–41].
Even though one cannot discard mere play of chance 
as the culprit, there are many other objective reasons for 
the differences observed. Besides drug tolerability and 
ease of administration, trial design and population can 
heavily influence the outcomes. As we describe, there are 
several important differences between the ways GLP-1 
RA CVOTs were designed. For the REWIND [33] and 
EXSCEL [26] trials, the primary analysis aim was to show 
superiority, whereas for the others it was to show non-
inferiority. Even for the non-inferiority trials, the upper 
limit of the 95% CI differed, with SUSTAIN-6 [25] and 
PIONEER 6 [31] using 1.8 rather than the more common 
1.3 limit. Inclusion criteria also varied significantly, as we 
highlight above, as well as concomitant antidiabetic med-
ication (Table 2).
The differences in trials design can be fully appreci-
ated by analyzing the baseline population characteristics 
(Table  3). Trials using a higher upper limit for the 95% 
CI (SUSTAIN-6 [25] and PIONEER 6 [31]) had lower 
numbers of participants. The proportion of females was 
also different, being higher in the REWIND [33, 34] trial, 
that was specifically designed to include more women. 
Usually trials designed to evaluate CVO hat more male, 
because CV events are more frequent in males. There are 
also important differences in the mean baseline HbAc1 
levels, as a consequence mainly of differences in inclu-
sion/exclusion criteria. These trials were event-driven, 
and therefore their duration and mean follow-up times 
differ, varying from 1.3 (PIONEER 6 [32]) to 5.4  years 
(REWIND [34]), at least partially resulting from the dif-
ferent designs.
Perhaps most importantly, the trials differed substan-
tially in the percentages of people with eCVD and/or CV 
risk factors. Most of them included a mixture of patients 
with eCVD and others with risk factors only, but the 
ELIXA [21, 22] and Harmony Outcomes [29, 30] trials 
had 100% of patients with eCVD, whereas the ESXCEL 
[26–28] trial included patients without CV risk factors.
An indirect way of assessing the risk of the population 
included in the different studies is to look at the event rate 
in the placebo group. In fact, in all the studies the event 
rate was higher than 2 per 100 patient-years (Table  4), 
which roughly corresponds to a 10-year event rate above 
20%. We can conclude that we are always looking at very 
high-risk patients (formerly considered as coronary-
risk equivalent [42]). Nonetheless, the event rate varied 
across the different trials, and seems to reflect differences 
in the population. For example, the lowest placebo event 
rate (2.7/100 patient-yr) was seen in the REWIND [34] 
trial, which is by far the one with the lowest percentage 
of patients with eCVD (31.5%), whereas the two highest 
placebo event rates were seen in the ELIXA [22] and Har-
mony Outcomes [30] trials (6.3 and 5.9/100 patient-yr, 
respectively), which were the only two with a population 
consisting exclusively of patients with eCVD.
A post-hoc analysis of the SUSTAIN-6 trial [43] 
showed that semaglutide reduces the risk of MACE in all 
the subgroups analyzed, which included grouping by age, 
gender, and CV risk. The duration of diabetes at baseline, 
however, seems to affect the outcomes, as demonstrated 
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by a post-hoc analysis of the SUSTAIN-6 and LEADER 
trials [44]. A recent meta-analysis of all the discussed 
GLP-1 RA CVOTs found no significant heterogeneity 
across subgroups, which included primary versus sec-
ondary prevention, HbAc1 levels, length of follow-up, 
daily versus weekly administration, homology of the drug 
to human GLP-1, BMI, age, or baseline eGFR [45].
Nonetheless, the use of different definitions of eCVD 
in the different CVOTs that evaluated GLP-1 RA makes 
it difficult to compare results, even in a meta-analysis 
context; in fact, a patient-level meta-analysis would be 
needed, and that would involve data sharing between the 
research teams of all trials. This is of special importance 
due to the heterogeneity of the results regarding MACE 
and its different components, and raises questions 
about the generalizability of the results to the majority 
of the T2D population that does not have eCVD. Since 
reduction of cardiovascular disease occurred driven by 
reductions in either MI (HARMONY) [30], stroke (SUS-
TAIN-6 [25] and REWIND [34]) or CV death (LEADER) 
[24], it is of interest to understand if different drugs con-
fer different benefits to patients. In this regard, PAD is 
relevant for several reasons: it frequently affects mid-
dle-aged and older patients with T2D [2] and the crite-
ria for its presence were heterogeneous in the different 
studies. Furthermore, in the REWIND [34] trial PAD 
was only considered as present if patients had been sub-
mitted to revascularization. Bearing this in mind, it is 
conceivable that the same patient with PAD would have 
been included in the group without CVD in one study 
and in the one with CVD in the other. Considering that 
PAD may be the most frequent manifestation of CVD 
in patients with T2D [2], a careful interpretation of the 
available data should be sought, precluding a direct gen-
eralizability of the results found in trials with a high pro-
portion of patients with eCVD.
Another approach to evaluate the generalizability of 
the results is to use the specific inclusion criteria of the 
different GLP-1RA CVOTs in the real-world setting, ana-
lyzing the proportion of patients that would fulfill inclu-
sion criteria. This approach was used in different studies 
[46–48]. Overall, between 40 and 60% of the real-world 
diabetic population would meet the inclusion criteria. Of 
note, using the same real-world dataset, there was high 
heterogeneity between the proportion of patients that 
could have been included in different trials, emphasizing 
the problem of generalizability. However, a recent study 
evaluated the transposition of cardiovascular outcome 
trial effects to the real-world population using CVOT 
stratum-specific effects, showing that the cardiovascular 
benefits are transferable to a much different real-world 
population [49].
Conclusions
We strongly believe that a fair and clinically useful com-
parison between the results of GLP-1 RA CVOTs dis-
cussed would involve post-hoc and meta-analyses in 
which the classification and grouping of patients would 
be done based on baseline clinical characteristics of each 
patient, which would then be grouped into different 
eCVD or CV risk factor classes designed according to the 
same definitions. Ideally, future CVOTs for antidiabetic 
drugs should be harmonized in such a way that consist-
ent criteria are used across them, making comparisons 
between different drugs possible. This is particularly 
important in this new age of T2D management, in which 
personalized care based on patient’s characteristics 
should dictate the best drug therapy for each individual.
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